Publications by authors named "Bhagya Harindi Loku Waduge"
Article Synopsis
- Sirolimus-coated balloons (SCBs) show promise for treating de novo lesions, but there is limited long-term data available on their effectiveness and safety.
- This study analyzed outcomes from 771 patients who received SCBs, focusing on metrics like cardiac death, myocardial infarction, and revascularization, with a median follow-up of 640 days.
- Results indicated low rates of adverse events, including a 1.3% rate of cardiac death and 8% overall major adverse cardiac events (MACE), suggesting SCBs may be a viable treatment option in real-world settings.
Drug coated balloons (DCB) are increasingly being used in coronary intervention. Most of their use is currently restricted to in stent restenosis, however, they are also being used to treat some de novo lesion subsets (especially small vessels) and in patients unable to take dual antiplatelet therapy beyond a month. Calcified lesions pose a significant challenge to coronary intervention from lesion preparation to the delivery of drug to the vessel wall.
View Article and Find Full Text PDFA 43-year-old woman presented with an 8-week history of fatigue and recurrent right sided nasal bleeds progressing to significant pain and swelling on the right side of her face. Clinical examination revealed a friable mass in her right nasal passage. A biopsy and staging positron emission tomography-CT scan confirmed the diagnosis of a T4 N1 M1 BRAF wild type mucosal melanoma.
View Article and Find Full Text PDF